Product Summary

Cat. No.
KIT 036
Assay range
10-1000 pg/mL
Assay time
4 hours
Limit of detection
4 pg/mL
Sample dilution
1/500 (Urine from healthy subjects)
Species reactivity (positive)
None
Storage
4°C
Target
Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Background
NGAL is a new early biomarker for diagnosing acute kidney injury (AKI). Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
Regulatory status
Not available in the USA for in vitro diagnostic use. For in vitro diagnostic use in the European Union and Canada. For research use only in all other territories.
Patent status
This product is protected by one or more U.S., European and/or foreign patents as listed on www.bioporto/about us/patents

Scientific References

24518531 – Hasse-Fielitz A, Haase M, Devarajan P (2014) Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51:335-351

 

23341719 – Cho E, Yang HN, Jo SK, Cho WY, Kim HK (2013) The role of urinary liver-type fatty acid-binding protein in critically ill patients. J Korean Med Sci. 28:100-105

 

23428967 – Di NM, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, Picca S, Muraca M, Cogo P (2013)Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. Blood Purif 35: 172-176

 

23388612 – Kashani K et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17:R25

 

23605129 – Kift RL et al (2013) A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem. 50: 236-244

 

Cat. No.
KIT 036
Assay range
10-1000 pg/mL
Assay time
4 hours
Limit of detection
4 pg/mL
Sample dilution
1/500 (Urine from healthy subjects)
Species reactivity (positive)
None
Storage
4°C
Target
Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Background
NGAL is a new early biomarker for diagnosing acute kidney injury (AKI). Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
Regulatory status
Not available in the USA for in vitro diagnostic use. For in vitro diagnostic use in the European Union and Canada. For research use only in all other territories.
Patent status
This product is protected by one or more U.S., European and/or foreign patents as listed on www.bioporto/about us/patents

24518531 – Hasse-Fielitz A, Haase M, Devarajan P (2014) Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51:335-351

 

23341719 – Cho E, Yang HN, Jo SK, Cho WY, Kim HK (2013) The role of urinary liver-type fatty acid-binding protein in critically ill patients. J Korean Med Sci. 28:100-105

 

23428967 – Di NM, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, Picca S, Muraca M, Cogo P (2013)Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. Blood Purif 35: 172-176

 

23388612 – Kashani K et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17:R25

 

23605129 – Kift RL et al (2013) A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem. 50: 236-244

 

More Information

+

Simple ELISA format with ready-to-use calibrators and working solutions, and pre-coated ELISA strips. All incubations are performed at room temperature. Automation is possible on open ELISA workstations.

×